	US 12,145,970 B2
	Twisted gastrulation polypeptides and uses thereof
Rajasekhar Naga Venkata Sai Suragani, Wrentham, MA (US); Asya Grinberg, Lexington, MA (US); and Dianne Sako, Medford, MA (US)
Assigned to ACCELERON PHARMA INC., Cambridge, MA (US)
Filed by ACCELERON PHARMA INC., Cambridge, MA (US)
Filed on Feb. 27, 2023, as Appl. No. 18/175,163.
Application 18/175,163 is a division of application No. 16/332,724, abandoned, previously published as PCT/US2017/051727, filed on Sep. 15, 2017.
Claims priority of provisional application 62/395,088, filed on Sep. 15, 2016.
Prior Publication US 2023/0234998 A1, Jul. 27, 2023
Int. Cl. A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61P 7/06 (2006.01); C07K 14/47 (2006.01); C07K 14/52 (2006.01); C07K 19/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/4703 (2013.01) [A61K 38/17 (2013.01); A61K 45/06 (2013.01); A61P 7/06 (2018.01); C07K 14/52 (2013.01); C07K 19/00 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)]

12 Claims

1. A method of treating anemia in a subject, comprising administering to the subject a fusion protein comprising a Twisted Gastrulation (TWSG) polypeptide and a fragment crystallizable region (Fc) polypeptide, wherein the TWSG polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 8.